PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24525311-10 2014 Additionally, enoxaparin decreased plasma TNF-alpha by 22% (P<0.01), increased hepatic lipase (HL) activity by 81% (P<0.01), along with a 2-fold increase in ISI (P<0.01). Enoxaparin 14-24 lipase C, hepatic type Homo sapiens 82-96 24525311-10 2014 Additionally, enoxaparin decreased plasma TNF-alpha by 22% (P<0.01), increased hepatic lipase (HL) activity by 81% (P<0.01), along with a 2-fold increase in ISI (P<0.01). Enoxaparin 14-24 lipase C, hepatic type Homo sapiens 98-100 24525311-13 2014 CONCLUSIONS: The association of the effect on post-prandial metabolism, plasma TNFalpha level and HL activity during prolonged enoxaparin treatment may support the hypothesis that the beneficial outcome of enoxaparin may possibly be linked to anti-inflammatory and lipase-potentiating impact. Enoxaparin 127-137 lipase C, hepatic type Homo sapiens 98-100 24525311-13 2014 CONCLUSIONS: The association of the effect on post-prandial metabolism, plasma TNFalpha level and HL activity during prolonged enoxaparin treatment may support the hypothesis that the beneficial outcome of enoxaparin may possibly be linked to anti-inflammatory and lipase-potentiating impact. Enoxaparin 206-216 lipase C, hepatic type Homo sapiens 98-100